Pregled bibliografske jedinice broj: 514971
Clinical applicability of tumor marker CYFRA 21-1 in patients with NSCLC: a longitudinal study of 500 patients during 2 years
Clinical applicability of tumor marker CYFRA 21-1 in patients with NSCLC: a longitudinal study of 500 patients during 2 years // Gene Functional Analysis
San Francisco (CA), Sjedinjene Američke Države, 2001. (poster, nije recenziran, sažetak, znanstveni)
CROSBI ID: 514971 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Clinical applicability of tumor marker CYFRA 21-1 in patients with NSCLC: a longitudinal study of 500 patients during 2 years
Autori
Pavićević, Radomir ; Bialk, Peter ; Bubanović, Gordana ; Krajna, Ana ; Samaržija, Miroslav ; Pavićević, Lukrecija
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Gene Functional Analysis
/ - , 2001
Skup
Cambridge Healthtech Institute's fifth annual «Gene Funcional analysis: Genome 2001» tri-conference
Mjesto i datum
San Francisco (CA), Sjedinjene Američke Države, 08.03.2001. - 09.03.2001
Vrsta sudjelovanja
Poster
Vrsta recenzije
Nije recenziran
Ključne riječi
CYFRA 21-1; NSCLC; tumor marker
Sažetak
The clinical application of cytokeratin marker CYFRA 21-1 was standardized on 2000 patients. In all patients the star value of CYFRA 21-1 was determined before therapy (Roche Diagnoastics). Tumor marker CYFRA 21-1 was ssessed longitudinally 1 to 24 months after the therapy, or before the next therapy. On eto three months after the surgical treatment in 87% of the patients the marker values decreased to the healthy population level...
Izvorni jezik
Engleski
Znanstvena područja
Biologija, Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Klinika za plućne bolesti "Jordanovac"
Profili:
Radomir Pavićević
(autor)
Lukrecija Pavićević
(autor)
Gordana Bubanović
(autor)
Miroslav Samaržija
(autor)
Ana Franjević
(autor)